1. GPCR/G Protein Neuronal Signaling
  2. Amylin Receptor CGRP Receptor
  3. Davalintide

Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Davalintide

Davalintide Chemical Structure

CAS No. : 863919-85-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes[1][2].

Parmacokinetics[2]
Species Dose Route Indicator value
Rat 0.2 mg/kg s.c. Tmax 20 min
Rat 0.2 mg/kg s.c. T1/2 26 min
Rat 0.2 mg/kg s.c. Cmax 64.085 ng/mL
Rat 0.2 mg/kg s.c. AUC0-24 43.368 ng·h/mL
Rat 0.2 mg/kg s.c. Plasma Concentration 0.127 ng/mL
In Vivo

Davalintide (1.09-1087 μg/kg (mice); 5 μg/kg (rats), i.p., single dose) inhibits the food intake of fasting mice and overfed rats, and its efficacy and duration of action were both superior to Amylin[1].
Davalintide (1-100 μg/kg, i.p., single dose) does not affect the autonomous activities when food intake is reduced in rats, and its inhibitory effect on appetite is not mediated by adverse reactions such as nausea or aversion[1].
Davalintide (1-100 μg/kg, s.c., once daily, continuous infusion for 8 weeks) effectively reduces rats food intake and body weight with the weight loss mainly specific to fat reduction, while lean body mass preserved, and it has metabolic benefits that go beyond simply restricting food intake[1].
Davalintide (10 μg/kg, s.c., once daily, continuous infusion for 4 weeks) significantly reduces total calorie intake, decreases the preference for high-fat and tasty foods, and prompts rats to choose the standard feed[1].
Davalintide (10 μg/kg, i.p., single dose) relies on the Area Postrema and achieves the effect of suppressing obesity by more persistently activating the downstream neural pathways in rats[1].
Davalintide (10 μg/kg, s.c., single dose) significantly inhibits the increase in glucagon caused by arginine stimulation in anesthetized rats, and the inhibitory effect on glucagon is specific[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Acute food intake inhibition experiment established in fasted overnight NIH Swiss mice (24-30 g) and overfed Sprague-Dawley (SD) rats (weighing 394-461 g)[1]
Dosage: 1.09-1087 μg/kg (mice); 5 μg/kg (rats)
Administration: Intraperitoneal injection (i.p.), single dose
Result: And Amylin both significantly and dose-dependently inhibited acute food intake (mice ED₅₀: 87 μg/kg vs. Amylin 110 μg/kg)
Exhibited the duration of action significantly longer than that of Amylin (23 hours vs. 6 hours) in the experiment where obese rats were subjected to the dark cycle (the main feeding period).
Animal Model: Behavioral safety experiment established fasted Sprague-Dawley (SD) rats (weighing 325-425 g)[1]
Dosage: 1, 10, 100 μg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Dose-dependently and persistently reduced food intake and body weight (8-week ED₅₀ = 1.2 μg/kg/day).
Significantly reduced the level of plasma triglycerides.
Animal Model: Continuous infusion experiment (metabolic effect) established in obese rats induced by diet (Levin or SD rats, ~464 g), maintained on a 32% high-fat diet[1]
Dosage: 1, 3, 10, 100 μg/kg
Administration: Subcutaneous injection (s.c.), once daily for 8 weeks
Result: Dose-dependently and persistently reduced food intake and body weight (8-week ED₅₀ = 1.2 μg/kg/day).
Significantly reduced the level of plasma triglycerides.
Animal Model: Food preference experiment established in DIO rats (~ 515 g) provided with both standard feed and 32% high-fat feed for them to choose freely[1]
Dosage: 10 μg/kg
Administration: Subcutaneous injection (s.c.), once daily for 4 weeks
Result: Significantly reduced total calorie intake.
Significantly reduced the preference for high-fat and delicious foods, and prompted the animals to choose standard feed.
Animal Model: Energy metabolism experiment established in SD rats (~ 421 g), maintained on a 32% high-fat diet for 5 weeks[1]
Dosage: 30 μg/kg
Administration: Subcutaneous injection (s.c.), once daily for 4 weeks
Result: Exhibited the energy consumption (VO₂) of not different from that in the Vehicle group.
Slight but significant increased RQ values at the end of the second week.
Animal Model: Area postrema (AP) damage experiment established in SD rats (weighing 175-200 g) underwent AP lesion surgery or sham surgery, and the experiments were conducted several months after recovery[1]
Dosage: 10 μg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Significantly reduced food intake in the sham operation group.
Completely eliminated the effect of suppressing appetite in the AP lesion group.
Animal Model: Neuronal activation (c-Fos expression) established in SD rats (400 g), maintained on a 32% high-fat diet[1]
Dosage: 10 μg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: activated the same neural pathways to Amylin, but its effects lasted longer.
Animal Model: Glucagon inhibition experiment established in starved SD rats (250-280 g) and SD rats (350-370 g)[2]
Dosage: 10 μg/kg
Administration: Subcutaneous injection (s.c.), single dose
Result: Significantly inhibited the glucagon secretion stimulated by arginine.
Was no difference in blood glucose and insulin levels during the clamp period.
Molecular Weight

3624.03

Formula

C152H248N50O49S2

CAS No.
Sequence

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr-NH2 (disulfide bridge:Cys2-Cys7)

Sequence Shortening

KCNTATCVLGRLSQELHRLQTYPRTNTGSNTY-NH2 (disulfide bridge:Cys2-Cys7)

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Davalintide
Cat. No.:
HY-P11320
Quantity:
MCE Japan Authorized Agent: